Amgen, Inc. vs Global X Defense Tech ETF — how do they compare? Amgen, Inc. trades at $416.04 (market cap $224.14B), while Global X Defense Tech ETF trades at $69.89. The key difference: Amgen, Inc. pays a 2.43% dividend while Global X Defense Tech ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | SHLD | |
|---|---|---|
Market Cap | $224.14B | — |
Sector | Health | Sector/Thematic |
52-Week High | $417.20 | $78.02 |
52-Week Low | $271.18 | $58.20 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | — |
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
SHLD, the Global X Defense Tech ETF, trades at $69.74, down slightly by 0.16% today. Technical indicators show a bullish trend with strong moving average signals, though oscillators are neutral and RSI levels suggest overbought conditions. Recent news highlights increased institutional investment, with firms like Focus Financial Network raising stakes by 55.4% in Q2 2026 (Defense World, 2026-08-11). The ETF benefits from global defense spending trends, including a $20 billion UK military overhaul (Zacks Investment Research, 2026-07-02).
The outlook for SHLD is positive, driven by rising global defense budgets and technological advancements in defense sectors. Investment opportunities include diversified exposure to defense innovation, supported by institutional accumulation. Risks involve geopolitical shifts, potential tariff impacts from policies like Trump's new tariffs (Fool - Investing News, 2026-08-04), and valuation pressures if growth slows. The ETF's performance hinges on sustained military expenditure increases and contract awards.
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →